Back to
Dr Marianne Martinello
Senior Lecturer

Dr Marianne Martinello

MBBS PhD FRACP

Medicine & Health
The Kirby Institute

Marianne Martinello is an infectious diseases physician at Prince of Wales Hospital and St Vincent’s Correctional Health, a senior research fellow in the Viral Hepatitis Clinical Research Program at the Kirby Institute, and an NHMRC Early Career Fellow. As a clinician-researcher, she aims to optimise the diagnosis, treatment, and prevention of infectious diseases, particularly blood-borne viruses among vulnerable populations. Her research on direct-acting antiviral therapy in people with HCV infection is internationally recognised and has impacted policy and practice.

Phone
+61 (0)2 9385 0900
E-mail
mmartinello@kirby.unsw.edu.au
  • Book Chapters | 2021
    2021, 'HCV Elimination in Australia', in Hepatitis C: Epidemiology, Prevention and Elimination Volume 1, Springer, https://doi.org/10.1007/978-3-030-64649-3_11
    Book Chapters | 2020
    2020, 'Global elimination of hepatitis C virus by 2030: the optimistic view', in , Wiley, pp. 238 - 243, http://dx.doi.org/10.1002/9781119533481.ch40
    Book Chapters | 2020
    2020, 'Harm reduction strategies to prevent new infections and reinfections among people who inject drugs: how effective are they?', in , Wiley, pp. 106 - 111, http://dx.doi.org/10.1002/9781119533481.ch18
    Book Chapters | 2019
    2019, 'Cure and Control: What Will It Take to Eliminate HCV?', in Sofia M (ed.), HCV: The Journey from Discovery to a Cure: Volume II, Springer International Publishing, pp. 447 - 490, http://dx.doi.org/10.1007/7355_2018_56
    Book Chapters | 2017
    Martinello MK; Grebely J; Dore G, 2017, 'Protease, polymerase and assembly inhibitors for the treatment of hepatitis C virus infection', in Kucers' The Use of Antibiotics A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition - Three Volume Set, CRC Press, pp. 4409 - 4431, http://dx.doi.org/10.1201/9781315152110
    Book Chapters | 2017
    Mills J; Crowe SM; Martinello MK, 2017, 'Investigational antiviral drugs', in Kucers' The Use of Antibiotics A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition - Three Volume Set, CRC Press
    Book Chapters | 2014
    Matthews G; Martinello MK; van Beek I; Burns M, 2014, 'Exposure and acute viral hepatitis', in HIV, Viral Hepatitis and STIs: A Guide for Primary Care
  • Journal articles | 2023
    2023, 'Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients', Nature Communications, 14, pp. 687, http://dx.doi.org/10.1038/s41467-023-36295-5
    Journal articles | 2023
    2023, 'Clinical variation in the early assessment and management of suspected community-acquired meningitis: a multicentre retrospective study', Internal Medicine Journal, http://dx.doi.org/10.1111/imj.16076
    Journal articles | 2023
    2023, 'Effectiveness of direct-acting antiviral therapy among Aboriginal and Torres Strait Islander peoples with HCV infection in Australia: A national real-world cohort (REACH-C)', Journal of Viral Hepatitis, 30, pp. 386 - 396, http://dx.doi.org/10.1111/jvh.13803
    Journal articles | 2023
    2023, 'Hepatitis C virus-specific immune responses following direct-acting antivirals administered during recent hepatitis C virus infection', Journal of Viral Hepatitis, 30, pp. 64 - 72, http://dx.doi.org/10.1111/jvh.13761
    Journal articles | 2023
    2023, 'High activation levels maintained in receptor-binding domain–specific memory B cells in people with severe coronavirus disease 2019', Immunology and Cell Biology, 101, pp. 142 - 155, http://dx.doi.org/10.1111/imcb.12607
    Journal articles | 2023
    2023, 'Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study', The Lancet Public Health, 8, pp. e294 - e304, http://dx.doi.org/10.1016/S2468-2667(23)00056-7
    Journal articles | 2023
    2023, 'Universal hepatitis C virus screening and treatment as part of prenatal care', The Lancet Gastroenterology and Hepatology, 8, pp. 295 - 297, http://dx.doi.org/10.1016/S2468-1253(22)00421-6
    Journal articles | 2022
    2022, 'A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study', Viruses, 14, http://dx.doi.org/10.3390/v14071555
    Journal articles | 2022
    2022, 'Case report of a man with HIV presenting with malignant syphilis.', Sexual Health, http://dx.doi.org/10.1071/sh22161
    Journal articles | 2022
    2022, 'Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals', JHEP Reports, 4, pp. 100462 - 100462, http://dx.doi.org/10.1016/j.jhepr.2022.100462
    Journal articles | 2022
    2022, 'Clinical and Public Health Implications of Human T-Lymphotropic Virus Type 1 Infection', Clinical Microbiology Reviews, 35, pp. e0007821, http://dx.doi.org/10.1128/cmr.00078-21
    Journal articles | 2022
    2022, 'Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study.', Int J Drug Policy, 105, pp. 103706, http://dx.doi.org/10.1016/j.drugpo.2022.103706
    Journal articles | 2022
    2022, 'Evaluation of the hepatitis C cascade of care among people living with HIV in New South Wales, Australia: A data linkage study', Journal of Viral Hepatitis, 29, pp. 271 - 279, http://dx.doi.org/10.1111/jvh.13658
    Journal articles | 2022
    2022, 'Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study', Clinical Infectious Diseases, 75, pp. 1809 - 1819, http://dx.doi.org/10.1093/cid/ciac246
    Journal articles | 2022
    2022, 'High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH-C Study', Hepatology Communications, 6, pp. 496 - 512, http://dx.doi.org/10.1002/hep4.1826
    Journal articles | 2022
    2022, 'Longitudinal Characterization of Phagocytic and Neutralization Functions of Anti-Spike Antibodies in Plasma of Patients after Severe Acute Respiratory Syndrome Coronavirus 2 Infection', Journal of Immunology, 209, pp. 1499 - 1512, http://dx.doi.org/10.4049/jimmunol.2200272
    Journal articles | 2022
    2022, 'Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses', Cell Reports, 38, pp. 110345, http://dx.doi.org/10.1016/j.celrep.2022.110345
    Journal articles | 2022
    2022, 'Patterns and correlates of hepatitis C virus phylogenetic clustering among people living with HIV in Australia in the direct-acting antiviral era: A molecular epidemiology study among participants in the CEASE cohort', Health Science Reports, 5, http://dx.doi.org/10.1002/hsr2.719
    Journal articles | 2022
    2022, 'Perceptions of hepatitis C treatment and reinfection risk among HIV-positive men who have sex with men and engage in high risk behaviours for hepatitis C transmission: The CEASE qualitative study', International Journal of Drug Policy, 109, pp. 103828, http://dx.doi.org/10.1016/j.drugpo.2022.103828
    Journal articles | 2022
    2022, 'Persistent high-level shedding of cultivable SARS-CoV-2 Delta virus 33 days after onset of COVID-19 in a hospitalized patient with pneumonia', Journal of Medical Virology, 94, pp. 4043 - 4046, http://dx.doi.org/10.1002/jmv.27832
    Journal articles | 2022
    2022, 'Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: The ETHOS Engage Study', Drug and Alcohol Dependence, 237, pp. 109543, http://dx.doi.org/10.1016/j.drugalcdep.2022.109543
    Journal articles | 2022
    2022, 'Retreatment for hepatitis C virus direct-acting antiviral therapy virological failure in primary and tertiary settings: The REACH-C cohort', Journal of Viral Hepatitis, 29, pp. 661 - 676, http://dx.doi.org/10.1111/jvh.13705
    Journal articles | 2022
    2022, 'Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression', The Lancet HIV, 9, pp. e414 - e427, http://dx.doi.org/10.1016/S2352-3018(22)00077-7
    Journal articles | 2022
    2022, 'Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales', JHEP Reports, 4, pp. 100552 - 100552, http://dx.doi.org/10.1016/j.jhepr.2022.100552
    Journal articles | 2021
    2021, 'Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort', International Journal of Drug Policy, 96, pp. 103422, http://dx.doi.org/10.1016/j.drugpo.2021.103422
    Journal articles | 2021
    2021, 'Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability', Immunity, 54, pp. 2908 - 2921.e6, http://dx.doi.org/10.1016/j.immuni.2021.10.019
    Journal articles | 2021
    2021, 'Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection', Cell Reports Medicine, 2, pp. 100228, http://dx.doi.org/10.1016/j.xcrm.2021.100228
    Journal articles | 2021
    2021, 'Opportunities to Enhance Linkage to Hepatitis C Care Among Hospitalized People With Recent Drug Dependence in New South Wales, Australia: A Population-based Linkage Study', Clinical Infectious Diseases, 73, pp. 2037 - 2044, http://dx.doi.org/10.1093/cid/ciab526
    Journal articles | 2021
    2021, 'Prescribing of direct-acting antiviral therapy by general practitioners for people with hepatitis C in an unrestricted treatment program', Medical Journal of Australia, 215, pp. 332 - 333, http://dx.doi.org/10.5694/mja2.51204
    Journal articles | 2021
    2021, 'Progress towards Elimination of Hepatitis C Infection among People Who Inject Drugs in Australia: The ETHOS Engage Study', Clinical Infectious Diseases, 73, pp. E69 - E78, http://dx.doi.org/10.1093/cid/ciaa571
    Journal articles | 2021
    2021, 'Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection', Journal of Hepatology, 75, pp. 829 - 839, http://dx.doi.org/10.1016/j.jhep.2021.04.056
    Journal articles | 2020
    2020, 'Association between HTLV-1 infection and adverse health outcomes: a systematic review and meta-analysis of epidemiological studies', The Lancet Infectious Diseases, 20, pp. 133 - 143, http://dx.doi.org/10.1016/S1473-3099(19)30402-5
    Journal articles | 2020
    2020, 'Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO-C): An open-label, single-arm, phase 4, multicentre trial', Health Science Reports, 3, pp. e151, http://dx.doi.org/10.1002/hsr2.151
    Journal articles | 2020
    2020, 'Estimated uptake of hepatitis C direct-acting antiviral treatment among individuals with HIV co-infection in Australia: A retrospective cohort study', Sexual Health, 17, pp. 223 - 230, http://dx.doi.org/10.1071/SH19101
    Journal articles | 2020
    2020, 'Global elimination of hepatitis C virus by 2030: why not?', Nature Medicine, 26, pp. 157 - 160, http://dx.doi.org/10.1038/s41591-019-0706-x
    Journal articles | 2020
    2020, 'Hepatitis C elimination in Australia: progress and challenges', Medical Journal of Australia, 212, pp. 362 - 363, http://dx.doi.org/10.5694/mja2.50584
    Journal articles | 2020
    2020, 'Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis', Journal of Hepatology, 72, pp. 643 - 657, http://dx.doi.org/10.1016/j.jhep.2019.11.012
    Journal articles | 2020
    2020, 'Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study', Journal of Viral Hepatitis, 27, pp. 281 - 293, http://dx.doi.org/10.1111/jvh.13233
    Journal articles | 2020
    2020, 'Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV', AIDS, 34, pp. 1347 - 1358, http://dx.doi.org/10.1097/QAD.0000000000002562
    Journal articles | 2020
    2020, 'Modeling based response guided therapy in subjects with recent hepatitis C infection', Antiviral Research, 180, pp. 104862, http://dx.doi.org/10.1016/j.antiviral.2020.104862
    Journal articles | 2020
    2020, 'Moving towards Hepatitis C microelimination among people living with human immunodeficiency virus in Australia: The CEASE study', Clinical Infectious Diseases, 71, pp. 1502 - 1510, http://dx.doi.org/10.1093/cid/ciz985
    Journal articles | 2020
    2020, 'Progress Toward Hepatitis C Virus Elimination: Therapy and Implementation', Gastroenterology Clinics of North America, 49, pp. 253 - 277, http://dx.doi.org/10.1016/j.gtc.2020.01.005
    Journal articles | 2020
    2020, 'Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection', Hepatology, 72, pp. 7 - 18, http://dx.doi.org/10.1002/hep.31003
    Journal articles | 2020
    2020, 'Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial', Journal of Hepatology, 72, pp. 431 - 440, http://dx.doi.org/10.1016/j.jhep.2019.10.010
    Journal articles | 2020
    2020, 'The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial', Trials, 21, http://dx.doi.org/10.1186/s13063-020-04576-9
    Journal articles | 2020
    2020, 'Time to Detection of Hepatitis C Virus Infection with the Xpert HCV Viral Load Fingerstick Point-of-Care Assay: Facilitating a More Rapid Time to Diagnosis', Journal of Infectious Diseases, 221, pp. 2043 - 2049, http://dx.doi.org/10.1093/infdis/jiaa037
    Journal articles | 2020
    2020, 'Transmission of hepatitis C virus in HIV-positive and PrEP-using MSM in England', Journal of Viral Hepatitis, 27, pp. 721 - 730, http://dx.doi.org/10.1111/jvh.13286
    Journal articles | 2019
    2019, 'A latent class approach to identify multi-risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015', Journal of the International AIDS Society, 22, pp. e25222, http://dx.doi.org/10.1002/jia2.25222
    Journal articles | 2019
    2019, 'A systematic, deep sequencing-based methodology for identification of mixed-genotype hepatitis C virus infections', Infection, Genetics and Evolution, 69, pp. 76 - 84, http://dx.doi.org/10.1016/j.meegid.2019.01.016
    Journal articles | 2019
    2019, 'Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study', Journal of Viral Hepatitis, 26, pp. 969 - 979, http://dx.doi.org/10.1111/jvh.13112
    Journal articles | 2019
    2019, 'Management of acute HCV in the era of direct-acting antivirals: implications for elimination', The Lancet Gastroenterology and Hepatology, 4, pp. 256 - 257, http://dx.doi.org/10.1016/S2468-1253(19)30001-9
    Journal articles | 2019
    2019, 'SAT-233-Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review, meta-analysis, and meta-regression', Journal of Hepatology, 70, pp. e733 - e733, http://dx.doi.org/10.1016/s0618-8278(19)31466-5
    Journal articles | 2019
    2019, 'SAT-235-Low HCV reinfection incidence following DAA treatment scale-up in people living with HIV in Australia', Journal of Hepatology, 70, pp. e734 - e734, http://dx.doi.org/10.1016/s0618-8278(19)31468-9
    Journal articles | 2019
    2019, 'Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with acute and recent HCV infection', JOURNAL OF HEPATOLOGY, 70, pp. E231 - E231, http://dx.doi.org/10.1016/S0618-8278(19)30432-3
    Journal articles | 2019
    2019, 'Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study', JOURNAL OF HEPATOLOGY, 70, pp. E110 - E110, http://dx.doi.org/10.1016/S0618-8278(19)30196-3
    Journal articles | 2018
    Bajis S; Maher L; Treloar C; Hajarizadeh B; Lamoury FM J; Mowat Y; Schulz M; Marshall AD; Cunningham EB; Cock V; Ezard N; Gorton C; Hayllar J; Smith J; Whelan M; Martinello M; Applegate TL; Dore GJ; Grebely J, 2018, 'Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia', International Journal of Drug Policy, 61, pp. 23 - 30, http://dx.doi.org/10.1016/j.drugpo.2018.08.011
    Journal articles | 2018
    Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ, 2018, 'Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia', Journal of Viral Hepatitis, 25, pp. 640 - 648, http://dx.doi.org/10.1111/jvh.12852
    Journal articles | 2018
    Lamoury FM J; Bajis S; Hajarizadeh B; Marshall AD; Martinello M; Ivanova E; Catlett B; Mowat Y; Marks P; Amin J; Smith J; Ezard N; Cock V; Hayllar J; Persing DH; Kleman M; Cunningham P; Dore GJ; Applegate TL; Grebely J, 2018, 'Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay', Journal of Infectious Diseases, 217, pp. 1889 - 1896, http://dx.doi.org/10.1093/infdis/jiy114
    Journal articles | 2018
    Martinello M; Bhagani S; Gane E; Orkin C; Cooke G; Dore GJ; Petoumenos K; Applegate TL; Tu E; Marks P; Pagani N; Grebely J; Nelson M; Matthews GV, 2018, 'Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection', Journal of Viral Hepatitis, 25, pp. 1180 - 1188, http://dx.doi.org/10.1111/jvh.12917
    Journal articles | 2018
    Martinello M; Dore GJ; Matthews GV; Grebely J, 2018, 'Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs', Infectious Disease Clinics of North America, 32, pp. 371 - 393, http://dx.doi.org/10.1016/j.idc.2018.02.003
    Journal articles | 2018
    Martinello M; Hajarizadeh B; Dore GJ, 2018, 'Observations on the launch of new drugs for hepatitis C', Australian Prescriber, 41, pp. 4 - 5, http://dx.doi.org/10.18773/austprescr.2018.005
    Journal articles | 2018
    Martinello M; Hajarizadeh B; Grebely J; Dore GJ; Matthews GV, 2018, 'Management of acute HCV infection in the era of direct-acting antiviral therapy', Nature Reviews Gastroenterology and Hepatology, 15, pp. 412 - 424, http://dx.doi.org/10.1038/s41575-018-0026-5
    Journal articles | 2018
    2018, 'Erratum: Antiretroviral use in the CEASE cohort study and implications for direct-acting antiviral therapy in human immunodeficiency virus/hepatitis C virus coinfection (Open Forum Infect Diss (2016)3:2(ofw105) DOI: 10.1093/ofid/ofw105)', Open Forum Infectious Diseases, 5, http://dx.doi.org/10.1093/ofid/ofy033
    Journal articles | 2017
    Martinello M; Grebely J; Matthews GV, 2017, 'Direct-acting antivirals for acute HCV: how short can we go?', The Lancet Gastroenterology and Hepatology, 2, pp. 316 - 318, http://dx.doi.org/10.1016/S2468-1253(17)30043-2
    Journal articles | 2017
    2017, 'HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs', Current HIV/AIDS Reports, 14, pp. 110 - 121, http://dx.doi.org/10.1007/s11904-017-0358-8
    Journal articles | 2017
    2017, 'HCV reinfection incidence among individuals treated for recent infection', Journal of Viral Hepatitis, 24, pp. 359 - 370, http://dx.doi.org/10.1111/jvh.12666
    Journal articles | 2017
    2017, 'O7 Moving towards HCV elimination in HIV/HCV co- infection in Australia following universal access to interferon-free therapy', Journal of Virus Eradication, 3, pp. 3 - 3, http://dx.doi.org/10.1016/s2055-6640(20)30890-6
    Journal articles | 2017
    2017, 'P20 Monitoring the uptake of hepatitis C: direct acting antiviral treatment in Australia', Journal of Virus Eradication, 3, pp. 19 - 19, http://dx.doi.org/10.1016/s2055-6640(20)30761-5
    Journal articles | 2016
    Hajarizadeh B; Grebely J; Martinello M; Matthews GV; Lloyd AR; Dore GJ, 2016, 'Hepatitis C treatment as prevention: evidence, feasibility, and challenges', The Lancet Gastroenterology and Hepatology, 1, pp. 317 - 327, http://dx.doi.org/10.1016/S2468-1253(16)30075-9
    Journal articles | 2016
    Martinello M; Amin J; Matthews GV; Dore GJ, 2016, 'Prevalence and disease burden of HCV coinfection in HIV cohorts in the Asia pacific region: A systematic review and meta-analysis', AIDS Reviews, 18, pp. 69 - 80
    Journal articles | 2016
    Martinello M; Dore GJ; Skurowski J; Bopage RI; Finlayson R; Baker D; Bloch M; Matthews GV, 2016, 'Antiretroviral use in the CEASE cohort study and implications for direct-acting antiviral therapy in human immunodeficiency virus/hepatitis C virus coinfection', Open Forum Infectious Diseases, 3, http://dx.doi.org/10.1093/ofid/ofw105
    Journal articles | 2016
    Martinello M; Dore GJ, 2016, 'Editorial commentary: Interferon-free Hepatitis C treatment efficacy from clinical trials will translate to "Real World" outcomes', Clinical Infectious Diseases, 62, pp. 927 - 928, http://dx.doi.org/10.1093/cid/civ1227
    Journal articles | 2016
    Martinello M; Gane E; Hellard M; Sasadeusz J; Shaw D; Petoumenos K; Applegate T; Grebely J; Maire L; Marks P; Dore GJ; Matthews GV, 2016, 'Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study', Hepatology, 64, pp. 1911 - 1921, http://dx.doi.org/10.1002/hep.28844
    Journal articles | 2016
    Martinello M; Hellard M; Shaw D; Petoumenos K; Applegate T; Grebely J; Yeung B; Maire L; Iser D; Lloyd A; Thompson A; Sasadeusz J; Haber P; Dore GJ; Matthews GV, 2016, 'Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies', ANTIVIRAL THERAPY, 21, pp. 425 - 434, http://dx.doi.org/10.3851/IMP3035
    Journal articles | 2016
    Martinello M; Hellard M; Shaw D; Petoumenos K; Applegate T; Grebely J; Yeung B; Maire L; Iser D; Lloyd A; Thompson A; Sasadeusz J; Haber P; Dore GJ; Matthews GV, 2016, 'Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies', Antiviral therapy, 21, pp. 465, http://dx.doi.org/10.3851/IMP3073
    Journal articles | 2016
    Martinello M; Schteinman A; Alavi M; Williams K; Dore GJ; Day R; Matthews GV, 2016, 'The impact of ribavirin plasma concentration on the efficacy of the interferon-sparing regimen, sofosbuvir and ribavirin', ANTIVIRAL THERAPY, 21, pp. 127 - 132, http://dx.doi.org/10.3851/IMP2984
    Journal articles | 2016
    Phillips CJ; Wells NA; Martinello M; Smith S; Woodman RJ; Gordon DL, 2016, 'Authors’ reply', Infection and Drug Resistance, 9, pp. 241
    Journal articles | 2016
    Phillips CJ; Wells NA; Martinello M; Smith S; Woodman RJ; Gordon DL, 2016, 'Optimizing the detection of methicillin-resistant staphylococcus aureus with elevated vancomycin minimum inhibitory concentrations within the susceptible range', Infection and Drug Resistance, 9, pp. 87 - 92, http://dx.doi.org/10.2147/IDR.S107961
    Journal articles | 2016
    2016, 'Evaluating vancomycin susceptibility in Staphylococcus aureus Reply', INFECTION AND DRUG RESISTANCE, 9, pp. 241 - 241, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000384501900002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Journal articles | 2016
    2016, 'Evaluating vancomycin susceptibility in Staphylococcus aureus.', Infect Drug Resist, 9, pp. 241, http://dx.doi.org/10.2147/IDR.S114942
    Journal articles | 2015
    Martinello M; Matthews GV, 2015, 'Enhancing the detection and management of acute hepatitis C virus infection', International Journal of Drug Policy, 26, pp. 899 - 910, http://dx.doi.org/10.1016/j.drugpo.2015.07.003
    Journal articles | 2014
    Ingram PR; Murray RJ; Cheng AC; Blyth CC; Walls T; Fisher DA; Davis JS; Abbott I; Kanapathipillai R; Madigan V; McLellan D; Briggs S; King C; Hurley J; Lim LL; Kennedy K; Wilson H; Evans T; Maze M; Pithie A; Chong L; Leung G; McCann S; Lee LY; Wolfgang J; Day T; Silva GD; Martinello M; Gliddon T; Wilson M; Athan E; Pollard J; Harris P; Pachchigar R; Wehrhahn M; Moriarty P; Holland D; Langlands A; McBride S; Sherif M; Lim K; Choong K; Henderson A; Sowden D; Everts R; Manon M; Sud A; Read K; Yap R; Bursle E; Gluer R; Siebert D; Cross G; Francis J; Booth C; Dalton S; Ooi EL; Chih D; Dyer J; Clarke J; Grimwood K; Gwee A; Commons R; Majumdar S; Warren S; Manners D; Raby E; Radhakrishnan D; Keighley C; Dotel R; Paterson D; Best E; Aung AK; Paterson T; Hassell M; Newcombe J; Llorin R; Lye D; Giola M; Yew HS; Taylor J; Iredell J; Pollett S; Garg L; Jennings Z; Kapur A; Miyakis S; Parshuramkar D; Thu KM; Rasiah K; Bak N; Chen S; Cooley L; Gordon D; Howden B; McBryde E; Murdoch D; Peleg A; Ralph A; Robinson O, 2014, 'What do infectious diseases physicians do? A 2-week snapshot of inpatient consultative activities across Australia, New Zealand and Singapore', Clinical Microbiology and Infection, 20, pp. O737 - O744, http://dx.doi.org/10.1111/1469-0691.12581
    Journal articles | 2014
    Martinello M; Chow DH; Danta M; Matthews GV; Dore GJ, 2014, 'Regression of advanced fibrosis following virological response to anti-HCV therapy', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 29, pp. 85 - 85, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000343863000166&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Journal articles | 2014
    Martinello M; Chow DH; Danta M; Matthews GV; Dore GJ, 2014, 'Safety and efficacy of telaprevir and boceprevir in the "real world": an Australian experience', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 29, pp. 85 - 86, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000343863000167&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Journal articles | 2012
    Lavender CJ; Globan M; Johnson PD R; Charles PG P; Jenkin GA; Ghosh N; Clark BM; Martinello M; Fyfe JA M, 2012, 'Buruli ulcer disease in travelers and differentiation of Mycobacterium ulcerans strains from northern Australia', Journal of Clinical Microbiology, 50, pp. 3717 - 3721, http://dx.doi.org/10.1128/JCM.01324-12
    Journal articles | 2012
    Martinello M; Nelson A; Bignold L; Shaw D, 2012, '“We are what we eat!” Invasive intestinal mucormycosis: A case report and review of the literature', Medical Mycology Case Reports, 1, pp. 52 - 55, http://dx.doi.org/10.1016/j.mmcr.2012.07.003
  • Preprints | 2023
    2023, A unique cytotoxic CD4+T cells signature defines critical COVID-19, , http://dx.doi.org/10.1101/2023.02.17.23286059
    Conference Papers | 2022
    2022, 'Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study', in International Journal of Drug Policy, WILEY, pp. S146 - S147, http://dx.doi.org/10.1016/j.drugpo.2022.103706
    Conference Abstracts | 2022
    2022, 'Liver-related mortality among people with hepatitis B and C: a validation study using linked healthcare administrative datasets', in JOURNAL OF HEPATOLOGY, ELSEVIER, Vol. 77, pp. S560 - S560, http://dx.doi.org/10.1016/s0168-8278(22)01443-x
    Conference Abstracts | 2022
    2022, 'Trends in decompensated cirrhosis and hepatocellular carcinoma diagnosis among people with a hepatitis B notification in New South Wales: a population-based data linkage study', in JOURNAL OF HEPATOLOGY, ELSEVIER, Vol. 77, pp. S302 - S302, http://dx.doi.org/10.1016/s0168-8278(22)00971-0
    Preprints | 2022
    2022, Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients, , http://dx.doi.org/10.1101/2022.10.19.512954
    Preprints | 2022
    2022, Hepatitis C Virus Transmission Dynamics in a Global Cohort of Men Who Have Sex with Men with Recently Acquired Infection, , http://dx.doi.org/10.2139/ssrn.4125248
    Conference Abstracts | 2021
    2021, 'Evaluation of the HCV cascade of care among people with HIV/hepatitis C co-infection in New South Wales, Australia: a data linkage study', in JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, JOHN WILEY & SONS LTD, Vol. 24, pp. 19 - 19, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000713652900036&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Preprints | 2021
    2021, Longitudinal characterisation of phagocytic and neutralisation functions of anti-Spike antibodies in plasma of patients after SARS-CoV-2 infection, , http://dx.doi.org/10.1101/2021.12.21.473774
    Reports | 2021
    2021, Progress towards hepatitis C elimination among Aboriginal and Torres Strait Islander people in Australia: monitoring and evaluation report, The Kirby Institute, UNSW Sydney, Sydney, Australia, https://kirby.unsw.edu.au/report/progress-towards-hepatitis-c-elimination-among-aboriginal-and-torres-strait-islander-people
    Reports | 2020
    2020, Human T-lymphotropic virus type 1: technical report, World Health Organization, Geneve, https://apps.who.int/iris/handle/10665/339773
    Preprints | 2020
    2020, Long-term persistence of neutralizing memory B cells in SARS-CoV-2, , http://dx.doi.org/10.21203/rs.3.rs-92527/v1
    Conference Abstracts | 2019
    2019, 'HEPATITIS C VIRUS REINFECTION FOLLOWING ANTIVIRAL TREATMENT AMONG PEOPLE WHO USE OR INJECT DRUGS: A SYSTEMATIC REVIEW AND META-ANALYSIS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 38, pp. S50 - S51, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000494890100127&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2019
    2019, 'Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review, meta-analysis, and meta-regression', in JOURNAL OF HEPATOLOGY, ELSEVIER, AUSTRIA, Vienna, Vol. 70, pp. E733 - E733, presented at International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), AUSTRIA, Vienna, 10 April 2019 - 14 April 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000463481703223&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2019
    2019, 'Low HCV reinfection incidence following DAA treatment scale-up in people living with HIV in Australia', in JOURNAL OF HEPATOLOGY, ELSEVIER, AUSTRIA, Vienna, Vol. 70, pp. E734 - E734, presented at International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), AUSTRIA, Vienna, 10 April 2019 - 14 April 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000463481703225&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2019
    2019, 'Risk factors and patterns of HCV transmission amongst men who have sex with men', in HIV MEDICINE, WILEY, pp. 12 - 12, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000463022600024&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2019
    2019, 'SHORT COURSE DURATION SOFOSBUVIR/VELPATASVIR IS INFERIOR TO STANDARD DURATION THERAPY IN THE TREATMENT OF RECENTLY ACQUIRED HCV INFECTION: RESULTS FROM REACT STUDY', in HEPATOLOGY, WILEY, MA, Boston, Vol. 70, pp. 1487A - 1488A, presented at 70th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, MA, Boston, 08 November 2019 - 12 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000500824000056&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2018
    Martinello M; Cerrone M; Bhagani S; Gane E; Orkin C; Cooke G; Dore GJ; Petoumenos K; Applegate TL; Tu E; Marks P; Pagani N; Schoolmeesters A; Grebely J; Nelson M; Matthews GV, 2018, 'TARGET3D: high efficacy of 8 weeks paritaprevir/ritonavir/ombitasvir and dasabuvir among people with recent genotype 1 HCV infection', in HIV MEDICINE, WILEY, Vol. 19, pp. S151 - S152, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000430174700440&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2018
    2018, 'Evaluation of the Xpert fingerstick HCV viral load assay', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, FRANCE, Paris, pp. S167 - S167, presented at International Liver Congress (ILC), FRANCE, Paris, 11 April 2018 - 15 April 2018, http://dx.doi.org/10.1016/S0168-8278(18)30546-4
    Conference Abstracts | 2018
    2018, 'Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia', in Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia, Paris, France, presented at THE INTERNATIONAL LIVER CONGRESS 2018, Paris, France, 11 April 2018 - 15 April 2018
    Conference Presentations | 2017
    Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ, 2017, 'The path towards hepatitis C elimination in Australia following universal access to interferon-free treatments', Vol. 66, pp. S291 - S292, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)30899-1
    Conference Abstracts | 2017
    Martinello M; Bhagani S; Gane EJ; Orkin C; Cooke G; Kulasegaram R; Shaw D; Hellard M; Tu E; Filep E; Petoumenos K; Marks P; Grebely J; Dore GJ; Nelson M; Matthews G, 2017, 'Shortened therapy of 8 weeks duration with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with acute and recent genotype 1 HCV infection: The TARGET3D Study', in HEPATOLOGY, WILEY, DC, Washington, Vol. 66, pp. 574A - 575A, presented at 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, DC, Washington, 20 October 2017 - 24 October 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000412089801215&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2017
    Martinello M; Dore GJ; Bopage RI; Finlayson R; Baker D; Bloch M; Wilcox A; Filep E; Hellard M; Matthews GV, 2017, 'DAA treatment scale-up in HIV/HCV co-infection: characterisinga population at risk for reinfection', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S495 - S496, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31388-0
    Conference Presentations | 2016
    Hajarizadeh B; Grebely J; Matthews G; Martinello M; Dore G, 2016, 'Treatment uptake for chronic hepatitis C in Australia following universal access to interferon-free treatments', Vol. 64, pp. 948A - 948A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493804277&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2016
    Lamoury F; Hajarizadeh B; Martinello M; Soker A; Martinez D; Cunningham P; Cloherty GA; Marks P; Matthews G; Amin J; Grebely J; Dore G; Applegate TL, 2016, 'Hepatitis C virus core antigen: A simplified treatment monitoring tool among those with recent Hepatitis C virus infection, including for post-treatment relapse', in HEPATOLOGY, WILEY, MA, Boston, pp. 415A - 415A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493802113&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2016
    Martinello M; Hellard M; Shaw D; Petoumenos K; Applegate T; Grebely J; Yeung B; Maire L; Iser D; Lloyd A; Thompson A; Sasadeusz J; Haber P; Dore GJ; Matthews GV, 2016, 'Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: The ATAHC II and DARE-C i studies', in Antiviral Therapy, pp. 425 - 434, http://dx.doi.org/10.3851/IMP3035
    Conference Abstracts | 2016
    Martinello M; Petoumenos K; Grebely J; Gane E; Hellard M; Shaw D; Sasdeusz J; Applegate T; Lamoury F; Yeung B; Maire L; Dore G; Matthews G, 2016, 'INCIDENCE OF HCV REINFECTION AMONG TREATED INDIVIDUALS WITH RECENTLY ACQUIRED INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, Vol. 64, pp. S620 - S621, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)01152-1
    Conference Papers | 2016
    Martinello M; Schteinman A; Alavi M; Williams K; Dore GJ; Day R; Matthews GV, 2016, 'The impact of ribavirin plasma concentration on the eficacy of the interferon-sparing regimen, sofosbuvir and ribavirin', in Antiviral Therapy, pp. 127 - 132, http://dx.doi.org/10.3851/IMP2984
    Preprints |
    Hepatitis C Reinfection Risk Following Successful Therapy Among People Living with HIV: A Global Systematic Review, Meta-Analysis, and Meta-Regression, , http://dx.doi.org/10.2139/ssrn.3958916
    Preprints |
    Long-Term Persistence of Neutralizing Memory B Cells in SARS-CoV-2, , http://dx.doi.org/10.2139/ssrn.3732365
    Preprints |
    Maintenance of Broad Neutralising Antibodies and Memory B Cells 12 Months Post-Infection Is Predicted by SARS-CoV-2 Specific CD4+ T Cell Responses, , http://dx.doi.org/10.2139/ssrn.3920641
    Preprints |
    Moving Towards HCV Elimination Among People Living with HIV in Australia: Analysis of the CEASE Prospective Cohort Study, , http://dx.doi.org/10.2139/ssrn.3269607